JP2017527580A - 老化防止スキンケア組成物及びレジメン - Google Patents
老化防止スキンケア組成物及びレジメン Download PDFInfo
- Publication number
- JP2017527580A JP2017527580A JP2017513454A JP2017513454A JP2017527580A JP 2017527580 A JP2017527580 A JP 2017527580A JP 2017513454 A JP2017513454 A JP 2017513454A JP 2017513454 A JP2017513454 A JP 2017513454A JP 2017527580 A JP2017527580 A JP 2017527580A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- regimen
- biological
- composition
- genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 159
- 230000003712 anti-aging effect Effects 0.000 title description 30
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 139
- 239000013543 active substance Substances 0.000 claims abstract description 82
- 230000004186 co-expression Effects 0.000 claims abstract description 51
- 238000009472 formulation Methods 0.000 claims abstract description 37
- 230000032683 aging Effects 0.000 claims abstract description 23
- 230000008439 repair process Effects 0.000 claims abstract description 23
- 238000001784 detoxification Methods 0.000 claims abstract description 21
- 230000002068 genetic effect Effects 0.000 claims abstract description 16
- 238000007634 remodeling Methods 0.000 claims abstract description 12
- 230000009759 skin aging Effects 0.000 claims abstract description 9
- 230000037067 skin hydration Effects 0.000 claims abstract description 6
- 239000000284 extract Substances 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 38
- 239000002537 cosmetic Substances 0.000 claims description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 28
- 230000031018 biological processes and functions Effects 0.000 claims description 27
- 230000008569 process Effects 0.000 claims description 25
- 240000008886 Ceratonia siliqua Species 0.000 claims description 23
- 235000013912 Ceratonia siliqua Nutrition 0.000 claims description 22
- 239000004006 olive oil Substances 0.000 claims description 18
- 235000008390 olive oil Nutrition 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 16
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 13
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 10
- 230000021164 cell adhesion Effects 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 235000005152 nicotinamide Nutrition 0.000 claims description 10
- 239000011570 nicotinamide Substances 0.000 claims description 10
- 229960003966 nicotinamide Drugs 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 230000001105 regulatory effect Effects 0.000 claims description 9
- 230000000699 topical effect Effects 0.000 claims description 9
- -1 vitamin B3 compound Chemical class 0.000 claims description 9
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 240000000662 Anethum graveolens Species 0.000 claims description 5
- 229960003512 nicotinic acid Drugs 0.000 claims description 5
- 239000000523 sample Substances 0.000 claims description 5
- 229930003537 Vitamin B3 Natural products 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 230000002103 transcriptional effect Effects 0.000 claims description 3
- 235000019160 vitamin B3 Nutrition 0.000 claims description 3
- 239000011708 vitamin B3 Substances 0.000 claims description 3
- 238000000354 decomposition reaction Methods 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 230000003442 weekly effect Effects 0.000 claims 1
- 230000003796 beauty Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 109
- 230000000694 effects Effects 0.000 description 45
- 230000014509 gene expression Effects 0.000 description 23
- 230000008901 benefit Effects 0.000 description 22
- FGSPQNZCLMWQAS-GPXNEJASSA-N (2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FGSPQNZCLMWQAS-GPXNEJASSA-N 0.000 description 13
- 235000013399 edible fruits Nutrition 0.000 description 12
- 230000008236 biological pathway Effects 0.000 description 11
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000004140 cleaning Methods 0.000 description 9
- 210000002615 epidermis Anatomy 0.000 description 7
- 108010027628 palmitoyl-lysyl-threonyl-threonyl-lysyl-serine Proteins 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 206010040954 Skin wrinkling Diseases 0.000 description 6
- 238000009795 derivation Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000036571 hydration Effects 0.000 description 6
- 238000006703 hydration reaction Methods 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 230000037303 wrinkles Effects 0.000 description 6
- 101001043321 Homo sapiens Lysyl oxidase homolog 1 Proteins 0.000 description 5
- 102100021949 Lysyl oxidase homolog 3 Human genes 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 230000001815 facial effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000008591 skin barrier function Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000016942 Elastin Human genes 0.000 description 4
- 108010014258 Elastin Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 229920002549 elastin Polymers 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 3
- 240000007817 Olea europaea Species 0.000 description 3
- 206010040799 Skin atrophy Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 230000036548 skin texture Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 230000000475 sunscreen effect Effects 0.000 description 3
- 239000000516 sunscreening agent Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 235000007227 Anethum graveolens Nutrition 0.000 description 2
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 235000017367 Guainella Nutrition 0.000 description 2
- UEJYSALTSUZXFV-SRVKXCTJSA-N Rigin Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O UEJYSALTSUZXFV-SRVKXCTJSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003679 aging effect Effects 0.000 description 2
- 239000001264 anethum graveolens Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000004900 autophagic degradation Effects 0.000 description 2
- 230000007321 biological mechanism Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 230000036559 skin health Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- AKWSQGJVCCLJPB-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;3-aminopropanoic acid Chemical compound NCCC(O)=O.OC(=O)[C@@H](N)CC1=CNC=N1 AKWSQGJVCCLJPB-JEDNCBNOSA-N 0.000 description 1
- OLDGKSQBWGEFNM-FQEVSTJZSA-N (2s)-6-amino-2-(hexadecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCCCN OLDGKSQBWGEFNM-FQEVSTJZSA-N 0.000 description 1
- RJZNPROJTJSYLC-LLINQDLYSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O RJZNPROJTJSYLC-LLINQDLYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- 235000017311 Anethum sowa Nutrition 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- OLDGKSQBWGEFNM-UHFFFAOYSA-N Nalpha -palmitoyl-lysine Natural products CCCCCCCCCCCCCCCC(=O)NC(C(O)=O)CCCCN OLDGKSQBWGEFNM-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- LUNQZVCDZKODKF-PFVVTREHSA-L copper acetic acid (2S)-6-amino-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoate (2S)-6-amino-2-[[(2S)-2-[(2-amino-1-oxidoethylidene)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoate hydron Chemical compound [Cu+2].CC(O)=O.CC(O)=O.NCCCC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1.NCCCC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 LUNQZVCDZKODKF-PFVVTREHSA-L 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 238000013144 data compression Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000000370 laser capture micro-dissection Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 229960004738 nicotinyl alcohol Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- FJCFFCXMEXZEIM-UHFFFAOYSA-N oxiniacic acid Chemical compound OC(=O)C1=CC=C[N+]([O-])=C1 FJCFFCXMEXZEIM-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000015909 regulation of biological process Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000006254 rheological additive Substances 0.000 description 1
- 108010091078 rigin Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000006128 skin development Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/48—Thickener, Thickening system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
- A61K2800/884—Sequential application
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Pediatric Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
Abstract
Description
OLIVEM(登録商標)ブランドオリーブ油誘導体などのオリーブ油抽出物/誘導体は、とりわけ抗酸化活性、及び他の中和活性を提供すると考えられ、それは環境傷害に対する保護をもたらし得る(例えば、Skin Biomarkers Confirm the Anti−Oxidant Activity of Olive Derivatives and Yeast Ferment Filtrate、Finlayら、P&G 67th Annual Meeting of American Academy of Dermatology(2009)を参照のこと)。具体的なオリーブ油抽出物/誘導体としては、B&T SRLからOlivem(登録商標)400、Olivem(登録商標)450、又はOlivem(登録商標)460として入手可能なオリーブ油PEG−7カルボン酸ナトリウムが含まれる。
ビタミンB3化合物は、スキンケア活性物質として知られており、いくつかの化粧品スキンケア利益を提供すると考えられている(例えば、Bissettら、「Niacinamide:A B Vitamin that Improves Aging Facial Skin Appearance」、及びDraelos、「Clinical Situations Conducive to Proactive Skin Health and Anti−Aging Improvement」を参照のこと)。ビタミンB3化合物は、酸化防止及び美白効果を有するものとして知られている。本発明の組成物態様は、1つ又は複数のビタミンB3化合物、及びそれらの塩並びに誘導体を含んでもよい。前述のビタミンB3化合物の非限定的な例としては、ニコチン酸エステルが挙げられ、ニコチン酸の非血管拡張性エステル、ニコチニルアミノ酸、カルボン酸のニコチニルアルコールエステル、ニコチン酸N−オキシド、ナイアシンアミド、及びそれらの塩並びに誘導体、及びそれらの混合物が含まれる。具体的な実施形態では、ビタミンB3化合物は、ナイアシンアミドである。
本発明のイナゴマメ果実抽出物(INCI名:Ceratonia siliqua果実抽出物;CAS番号:84961−45−5)は、マメ科Fabaceaeに属するイナゴマメの木で成長する卵形の非多肉質のインゲン様の鞘から作製される。イナゴマメは、オリゴガラクトマンナンが豊富であり、これは、重要な生物学的活性物質であると考えられている。イナゴマメ果実の鞘には、一般的に、「イナゴマメナッツ(carob nuts)」と呼ばれる大きな種子が入っている。本明細書に用いるのに好適なイナゴマメ果実抽出物は、当該技術分野において既知のプロセスを用いて、果実の鞘、種子、又はこれらの組み合わせから得ることができる。イナゴマメ果実抽出物は、例えば、水、増粘剤、湿潤剤、溶媒、可溶化剤等の他の好適な材料を含んでよい。本明細書で使用するのに好適なイナゴマメ果実抽出物は、商品名Glyco−Repair(商標)でSilab S.A.(France)により商用に製造されている。この特定の抽出物製品は、約94%の水と、5%のイナゴマメ果実抽出物と、1%の他の材料とを含有する。
本発明のいくつかの組成物態様は、改善された皮膚弾性及び皮膚のハリの増加を含む、皮膚に美容利益を提供することが知られている、1つ又は複数の種類のイノンド抽出物を含んでもよい。本明細書で使用される「イノンド抽出物」とは、イノンド、イノンド種子、ディリー(dilly)、ディル(peucedanum graveolens)、蒔羅(anethum graveolens)、インドディル(anethum sowa)、及び関連する合成並びに誘導物質を指す。
本発明の組成物態様は、1つ又は複数のペプチドを含み得る。本明細書で、「ペプチド」とは、10個以下のアミノ酸を含有するペプチド、その誘導体、異性体、及び金属イオン(例えば、銅、亜鉛、マンガン及びマグネシウム)のような他の種との錯体を指す。本明細書で使用するとき、ペプチドとは、天然起源ペプチド及び合成ペプチドの両方を指す。ペプチドは、ジ−、トリ−、テトラ−、ペンタ−、及びヘキサ−ペプチド、それらの塩類、異性体、誘導体、並びにそれらの混合物であり得る。有用なペプチド誘導体の例としては、大豆タンパク質由来のペプチド(Silab,FranceからのRidulisse C(商標))、カルノシン(β−アラニン−ヒスチジン)、パルミトイル−リジン−トレオニン(pal−KT)及びパルミトイル−リジン−トレオニン−トレオニン−リジン−セリン(pal−KTTKS、100ppmのpal−KTTKSを含有するMATRIXYL(登録商標)として知られている組成物内で入手可能)、パルミトイル−グリシン−グルタミン−プロリン−アルギニン(pal−GQPR、RIGIN(登録商標)として知られている組成物内で入手可能))、これら3つはSederma(France)から入手可能、アセチル−グルタメート−グルタメート−メチオニン−グルタミン−アルギニン−アルギニン(Ac−EEMQRR;Argireline(登録商標)、並びにCu−ヒスチジン−グリシン−グリシン(Cu−HGG、IAMIN(登録商標)としても知られている)が挙げられるが、これらに限定されない。
レジメン2:Bを適用し、水ですすぎ、直後にAを適用する;
レジメン3:Cを適用し、水ですすぎ、直後にCを適用する;
Claims (13)
- 老化するヒト皮膚の外観の改善に有効な多段階レジメンであって、前記レジメンが、
(a)皮膚老化の徴候を示す皮膚の目標部分を特定する工程と、
(b)皮膚洗浄及び/又は皮膚解毒、及び/又は皮膚水和に関連する1つ又は複数の生物学的テーマについての遺伝的共発現モジュールから導出された固有遺伝子(eigengene)を転写的にアップレギュレートする能力を有する少なくとも1つの活性物質を含む第1の配合物を、前記皮膚の目標部分に局所的に適用する工程と、
(c)皮膚修復及び/又は再構築に関連する1つ又は複数の生物学的テーマについての共発現モジュールから導出された固有遺伝子を転写的にアップレギュレートする能力を有する少なくとも1つの活性物質を含む第2の配合物を、前記皮膚の目標部分に局所的に適用する工程と、を含み、
(c)の適用が、(b)の適用に続いて行われる、レジメン。 - 少なくとも1週、少なくとも1ヶ月、及び少なくとも1年から選択される時間枠にわたって投与される、少なくとも毎日及び少なくとも1日2回から選択される投与計画で実施され、好ましくは、投与計画が、少なくとも1週の時間枠にわたって、少なくとも1日1回投与されるものである、請求項1に記載のレジメン。
- 前記(c)の適用が、前記(b)の適用の実質的に直後に続く、請求項1に記載のレジメン。
- 老化皮膚の外観を改善することが、暦年齢と外見年齢との間の負の不一致(negative discordance)の大きさを減少させることと、暦年齢と外見年齢との間の正の不一致(positive discordance)の大きさを保ち又は増大させることとを含む、請求項1に記載のレジメン。
- 遺伝的共発現モジュールが、(i)生物学的年齢と外見年齢との間の正の不一致を示す集団において転写的にアップレギュレートされている遺伝子の集合(a set of genes)と、(ii)(i)に実質的に表されたテーマから選択される1つ又は複数の生物学的テーマに関連する遺伝子の集合との共通集合(intersecting set)を含む、請求項1に記載のレジメン。
- 固有遺伝子が、特異値分解のプロセスによって、共発現モジュールについて得られる、請求項1に記載のレジメン。
- 別々に収容された第1のスキンケア組成物及び第2のスキンケア組成物と、前記第1の組成物を皮膚の目標領域に適用した後、前記第2の組成物を前記皮膚の目標領域に適用するための使用説明書と、任意に、前記第1及び/又は前記第2のスキンケア組成物の前記皮膚の目標領域への局所適用をもたらすための少なくとも1つのアプリケータとを含む、化粧料皮膚処置キットであって、
前記第1の組成物が、前記皮膚の目標部分に対して、皮膚洗浄及び/又は皮膚解毒に関連する1つ又は複数の生物学的テーマについての遺伝的共発現モジュールから導出された固有遺伝子を転写的にアップレギュレートする能力を有する少なくとも1つの活性物質を含むように配合され、前記第2の組成物が、皮膚修復及び/又は再構築に関連する1つ又は複数の生物学的テーマについての共発現モジュールから導出された固有遺伝子を転写的にアップレギュレートする能力を有する少なくとも1つの活性物質を含むように配合される、キット。 - 前記皮膚洗浄及び/又は皮膚解毒に関連する1つ又は複数の生物学的テーマが、表1に記載される生物学的テーマから選択され、前記皮膚修復及び/又は再構築に関連する1つ又は複数の生物学的テーマが、表2に記載される生物学的テーマから選択され、好ましくは、前記生物学的テーマが、細胞接着を含む、請求項1〜7のいずれか一項に記載のキット又はレジメン。
- 前記皮膚洗浄及び/又は皮膚解毒に関連する1つ又は複数の生物学的テーマについての遺伝的共発現モジュールから導出された固有遺伝子を転写的にアップレギュレートする能力を有する少なくとも1つの活性物質が、パルミトイルペプチド誘導体及びイナゴマメ種子(carob seed)誘導体のうちの1つ又は複数から選択され、前記皮膚修復及び/又は再構築に関連する1つ又は複数の生物学的テーマについての共発現モジュールから導出された固有遺伝子を転写的にアップレギュレートする能力を有する少なくとも1つの活性物質が、パルミトイルペプチド誘導体、ビタミンB3化合物、イノンド抽出物(dill extract)誘導体、及びオリーブ油誘導体のうちの1つ又は複数から選択される、請求項7に記載のキット。
- 前記パルミトイルペプチド誘導体が、Pal−KTを含み、前記イナゴマメ種子誘導体が、Glyco−Repair(商標)を含み、好ましくは、前記Pal−KTが、0.01%〜約10%の量で配合物中に存在し、前記Glyco−Repair(商標)が、0.0001%〜15%の量で配合物中に存在する、請求項9に記載のキット。
- 前記パルミトイルペプチド誘導体が、Pal−KTTKSを含み、前記ビタミンB3化合物が、ナイアシンアミドを含み、前記イノンド抽出物誘導体が、Lys’lastine(登録商標)Vを含み、前記オリーブ油誘導体が、Olivem(登録商標)460を含み、好ましくは、前記Pal−KTTKSが、0.01%〜約10%の量で配合物中に存在し、前記ナイアシンアミドが、0.1%〜約10%の量で配合物中に存在し、Lys’lastine(登録商標)Vが、約0.001%〜約7.0%の量で配合物中に存在し、前記Olivem(登録商標)460が、0.0005〜0.01%の量で配合物中に存在する、請求項9に記載のキット。
- ヒト皮膚の所望の美容表現型(cosmetic phenotype)に関連する固有遺伝子を転写的にアップレギュレートするのに有効な薬剤を特定するための方法であって、前記方法が、前記所望の美容表現型を示すヒト皮膚において転写的にアップレギュレートされている遺伝子の集合及び1つ又は複数の生物学的テーマに関連する遺伝子の集合から決定された共発現モジュールについての固有遺伝子を導出する工程と、推定薬剤(putative agent)で皮膚を処置する工程と、前記処置された皮膚中の前記固有遺伝子の転写評価(transcriptional assessment)を行う工程と、前記固有遺伝子が前記処置された皮膚においてアップレギュレートされている場合、前記推定薬剤を有効薬剤として特定する工程と、を含む、方法。
- 所望の美容表現型において差次的に発現されている遺伝子の第1の集合及び前記遺伝子の第1の集合において過剰出現する生物学的過程に関与する遺伝子の第2の集合の共発現モジュールから導出された固有遺伝子であって、好ましくは、プローブ集合が、前記共発現モジュール中の前記遺伝子のそれぞれについて、少なくとも1つのmRNAプローブを含む、固有遺伝子。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462049972P | 2014-09-12 | 2014-09-12 | |
US62/049,972 | 2014-09-12 | ||
PCT/US2015/049604 WO2016040752A1 (en) | 2014-09-12 | 2015-09-11 | Anti-aging skin care compositions and regimens |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2017527580A true JP2017527580A (ja) | 2017-09-21 |
Family
ID=54150740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017513454A Pending JP2017527580A (ja) | 2014-09-12 | 2015-09-11 | 老化防止スキンケア組成物及びレジメン |
Country Status (3)
Country | Link |
---|---|
US (2) | US10639288B2 (ja) |
JP (1) | JP2017527580A (ja) |
WO (2) | WO2016040752A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200150131A1 (en) * | 2017-05-04 | 2020-05-14 | Siwa Corporation | Diagnostic advanced glycation end-product antibodies |
US11771637B2 (en) * | 2021-01-22 | 2023-10-03 | The Procter & Gamble Company | Skin care composition and method of using the same |
US11571378B2 (en) | 2021-01-22 | 2023-02-07 | The Procter & Gamble Company | Skin care composition and method of using the same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013508322A (ja) * | 2009-10-23 | 2013-03-07 | リポテック,エセ.ア. | 皮膚、粘膜および/または毛髪の治療および/またはケアに使用するペプチド、ならびに化粧料または医薬品組成物におけるその使用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5997890A (en) | 1997-05-23 | 1999-12-07 | The Procter & Gamble Company | Skin care compositions and method of improving skin appearance |
US6492326B1 (en) | 1999-04-19 | 2002-12-10 | The Procter & Gamble Company | Skin care compositions containing combination of skin care actives |
US6696049B2 (en) | 2000-07-10 | 2004-02-24 | The Procter & Gamble Company | Cosmetic compositions |
CN101621987B (zh) | 2007-02-28 | 2013-08-21 | 宝洁公司 | 包含孟加拉榕树植物提取物的个人护理组合物 |
FR2947727B1 (fr) | 2009-07-07 | 2011-08-05 | Sothys Paris | Composition cosmetique a usage topique, trousse en comportant, procede cosmetique modulable en fonction du vieillissement de la peau la mettant en oeuvre |
US20120034613A1 (en) | 2010-08-03 | 2012-02-09 | Nse Products, Inc. | Apparatus and Method for Testing Relationships Between Gene Expression and Physical Appearance of Skin |
US20140163118A1 (en) * | 2011-05-03 | 2014-06-12 | Dermachip Inc. | Expression Signatures of Genes and Gene Networks Associated with Skin Aging |
EP2861758B1 (en) * | 2012-06-18 | 2019-01-09 | The Procter and Gamble Company | Methods for assessing anti-aging benefits of agents |
-
2015
- 2015-09-11 US US14/851,418 patent/US10639288B2/en active Active
- 2015-09-11 WO PCT/US2015/049604 patent/WO2016040752A1/en active Application Filing
- 2015-09-11 JP JP2017513454A patent/JP2017527580A/ja active Pending
- 2015-09-14 US US14/853,051 patent/US20160074291A1/en not_active Abandoned
- 2015-09-14 WO PCT/US2015/049937 patent/WO2016040931A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013508322A (ja) * | 2009-10-23 | 2013-03-07 | リポテック,エセ.ア. | 皮膚、粘膜および/または毛髪の治療および/またはケアに使用するペプチド、ならびに化粧料または医薬品組成物におけるその使用 |
Non-Patent Citations (4)
Title |
---|
"FACIAL KIT", DATABASE GNPD [ONLINE], JPN6018005734, June 2009 (2009-06-01), ISSN: 0003903703 * |
"REGIMEN KIT", DATABASE GNPD [ONLINE], JPN6018005733, August 2012 (2012-08-01), ISSN: 0003903702 * |
"SKIN TIGHTENING SERUM", DATABASE GNPD [ONLINE], JPN6018005735, September 2010 (2010-09-01), ISSN: 0003903704 * |
FU J J J; HILLEBRAND G G; ET AL: "A RANDOMIZED, CONTROLLED COMPARATIVE STUDY OF THE WRINKLE REDUCTION BENEFITS OF A COSMETIC 以下備考", BRITISH JOURNAL OF DERMATOLOGY, vol. VOL:162, NR:3, JPN5017007867, 1 March 2010 (2010-03-01), GB, pages 647 - 654, ISSN: 0003903701 * |
Also Published As
Publication number | Publication date |
---|---|
WO2016040752A1 (en) | 2016-03-17 |
US20160074301A1 (en) | 2016-03-17 |
US10639288B2 (en) | 2020-05-05 |
WO2016040931A1 (en) | 2016-03-17 |
US20160074291A1 (en) | 2016-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4584991B2 (ja) | 皮膚化粧料及びシワ改善剤 | |
JP2010514774A (ja) | 肌の状態および外観を改善するための組成物およびその使用方法 | |
JP6664220B2 (ja) | 海草を含む化粧品組成物 | |
JP2017527580A (ja) | 老化防止スキンケア組成物及びレジメン | |
Mohiuddin | An extensive review of cosmetics in use | |
KR20220009424A (ko) | 피부 처리 요법, 성분 및 조성물을 선택하는 방법 | |
Weiss et al. | Evaluation of a novel anti-aging topical formulation containing cycloastragenol, growth factors, peptides, and antioxidants | |
CN112043640B (zh) | 一种组合物及其在制备抗糖基化的化妆品中的应用 | |
Pierard et al. | Kefoconazofe 2% Emulsion in the Treatment of Seborrheic Dermatitis | |
CA3007694A1 (en) | Personal care formulations comprising carmin protein | |
US10596095B2 (en) | Method for moisturizing skin using P-113 peptide | |
JP4579564B2 (ja) | シワ改善剤 | |
Kwon et al. | Reduction of enlarged facial pore using ion‐paired amino acid through enhancement in skin permeation and exfoliation: A placebo‐controlled in vivo study | |
CN104053425B (zh) | 基于胶体银和脱氧核糖核酸的协同组合的医学护肤组合物 | |
CN107875089A (zh) | 一种含有铁皮石斛的护肤品及其制备方法和应用 | |
JP2017067612A (ja) | 素材のスクリーニング方法及びキット | |
Meilinda et al. | The effect of using a traditional mask of Moringa leaves for dry facial skin care | |
FR2975002A1 (fr) | Procede de traitement cosmetique de la peau en deux etapes successives | |
KR102523118B1 (ko) | 아이소부탄을 유용성분으로 포함하는 헤어케어 조성물 | |
RU2816982C2 (ru) | Способ выбора режимов, ингредиентов и композиций для лечения кожи | |
JP2013512681A (ja) | 皮膚のバリア機能を改善するためのcertの発現を刺激する活性薬剤をスクリーニングするための方法 | |
Sari et al. | Comparing The Performance of SITH VCO Body Balm to Body Butter Using Blind-Test Method | |
Khin | The Efficacy of Malus Domestica Stem Cell Extract Cream for the Reduction of Peri Orbital Wrinkles | |
EP3302716A1 (en) | Methods for identifying circadian rhythm-dependent cosmetic agents for skin care compositions | |
van der Hoeven | Help the scalp recover from stress with ProRenew Complex CLR |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170309 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20170511 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20170522 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180227 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20181023 |